Candel Therapeutics' Prostate Cancer Treatment Shows Sustained…

Event summary

Candel Therapeutics presented new biomarker data at ASTRO 2026 showing sustained immune remodeling more than two years after aglatimagene besadenovec treatment in localized prostate cancer.
AI-enabled digital pathology analysis demonstrated significant increases in lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone.
80% of evaluable aglatimagene patients had negative prostate biopsies versus 63% of control patients two years post-treatment.
Aglatimagene significantly increased overall lymphocytic fraction and enhanced lymphocyte-tumor engagement in patients with residual tumor.
Candel plans to advance toward a Biologics License Application submission for aglatimagene.

The big picture

Candel Therapeutics' data underscores the potential of aglatimagene to induce durable immune responses in prostate cancer, a critical differentiator in the competitive oncology space. The sustained immune remodeling observed more than two years post-treatment suggests a paradigm shift in how localized prostate cancer could be managed, potentially expanding the role of immunotherapies in this indication. The company's strategic focus on advancing toward regulatory submission positions it to capitalize on the growing demand for innovative cancer treatments.

What we're watching

Regulatory Pathway: Whether Candel can successfully navigate the Biologics License Application process and secure FDA approval for aglatimagene.
Clinical Validation: How the sustained immune remodeling data will impact the adoption of aglatimagene in the treatment of localized prostate cancer.
Market Positioning: The pace at which Candel can differentiate aglatimagene from existing immunotherapies and establish its position in the prostate cancer treatment landscape.